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Autoimmune diseases with high population prevalence such as type 1 diabetes (T1D) develop as a result of
ill-defined interactions between putative environmental triggers and a constellation of genetic elements scat-
tered throughout the genome. In T1D, these interactions somehow trigger a loss of tolerance to pancreatic
b cells, manifested in the form of a chronic autoimmune response that mobilizes virtually every cell type of
the immune system and progressively erodes the host’s b cell mass. The five accompanying review articles
focus on key areas of T1D research, ranging from genetics and pathogenesis to prediction and therapy.
Here, I attempt to integrate and bring into focus themost salient points of these reviews in the context of other
findings, with an emphasis on identifying knowledge gaps and research opportunities.Introduction
T1D in both humans and rodents, including nonobese diabetic
(NOD)mice and BioBreeding rats, results from selective destruc-
tion of pancreatic b cells by T cells recognizing many autoanti-
gens (Lieberman and DiLorenzo, 2003; Tsai et al., 2008). Current
evidence suggests that initiation of T1D requires both CD4+ and
CD8+ T cells; that autoreactive T cells differentiate into effectors
by engaging b cell antigens (shed by a prior insult) on local
antigen-presenting cells (APCs); that initiating CD4+ T cells are
insulin reactive; and that CD8+ T cells play a major role as b cell
killers (Tsai et al., 2008) (Figure 1). Although the precise sequence
of events remains ill defined, recent years have brought forth
a renewed understanding of key immunological events.
Insulin-Specific CD4+ T Cells and T1D Initiation
In an accompanying review in this issue of Immunity, Stadinsky
et al. discuss the contribution of certain antigenic specificities
to T1D, with a focus on CD4+ T cells (Stadinsky et al., 2010).
Although insulin is only one among a growing list of T1D-relevant
autoantigens (Lieberman and DiLorenzo, 2003; Tsai et al., 2008),
several lines of evidence suggest that insulin autoreactivity,
particularly against the B:9–23 epitope, plays a key role in the
initiation of murine T1D. The NOD mouse expresses two
pre-proinsulin-coding genes, Ins1 and Ins2. Ins1 is exclusively
expressed in the pancreas, whereas Ins2 is expressed in both
the pancreas and certain epithelial cells of the thymic medulla
that coexpress the transcription factor Aire (medullary thymic
epithelial cells [mTECs]). A recent study has established that
expression of Ins2 by mTECs is meant to tolerize pathogenic
insulin-autoreactive T cells, given that selective deletion of Ins2
in the mTECs of Ins1/ C57BL/6 mice (ID-TEC mice) triggered
a highly penetrant and aggressive form of diabetes (Fan et al.,
2009). Furthermore, NOD mice lacking both Ins1 and Ins2 but
expressing a functional insulin transgene encoding a mutant
B:9–23 epitope are diabetes resistant (Nakayama et al., 2005),
suggesting that B:9–23 autoreactivity lies upstream of other
T1D-associated T cell responses, a contention consistent with
observations in other experimental systems (French et al., 1997;Jaeckel et al., 2004; Krishnamurthy et al., 2006; The´bault-
Baumont et al., 2003). Collectively, these findings support the
view that insults induced by recruitment of insulin-reactive
T cells may provide the essential ‘‘hit and run’’ event that
unleashes all other diabetogenic T cell responses.
Why, where, and how insulin might be presented as a trig-
gering autoantigen, however, is unclear. A recent study has iden-
tified pathogenic CD4+ T cell clones in NOD mice that can only
recognize endogenous B:9–23 peptide presented by intraislet
dendritic cells (DCs), but not B:9–23 derived from the processing
of exogenous insulin (Mohan et al., 2010). It turns out that the
B:9–23 peptide recognized by these so-called ‘‘type B’’ CD4+
T cells derives from insulin contained within insulin secretory
granules. These CD4+ T cells would fail to recognize the B:9–23
epitope on mTECs and thus would be able to mount effective
responses against insulin-loaded DCs (Mohan et al., 2010).
Further studies of these and other T cell specificities in ID-TEC
mice may provide important new insights into how insulin might
contribute to T1D initiation. Notwithstanding its presumed key
role in the initiation of T1D, insulin is not the target antigen of
most islet-associated T cells at or near disease onset, at least
in mice (Mohan et al., 2010). Accordingly, selective targeting of
insulin autoreactivity may only have therapeutic significance
prior to disease initiation. As noted in Luo et al.’s review in this
issue of Immunity, human prevention trials using mature insulin
as tolerogen have yielded disappointing results (Luo et al., 2010).
Insulin-autoreactive CD4+ T cells have also been described in
T1D patients (Stadinsky et al., 2010), and there is evidence sug-
gesting that high-avidity insulin-reactive thymocytes may evade
central tolerance in such patients. For example, human T1D is
associated with a ‘‘variable number of tandem repeat’’ (VNTR)
polymorphism that lies upstream of the INS promoter and
reduces expression of insulin in the thymus (Bennett et al.,
1995; Vafiadis et al., 1997). Furthermore, as noted by Ziegler
and Nepom in an accompanying review, the prodiabetogenic
INS VNTR allele is associated with presence of high-avidity
CD4+ T cells against a dominant proinsulin epitope (Ziegler and
Nepom, 2010). In addition, patients carrying mutations in AIRE,Immunity 32, April 23, 2010 ª2010 Elsevier Inc. 437
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Figure 1. Intersection of T1D Pathways and
T1D-Associated Genes
High-avidity (HA) autoreactive CD4+ and CD8+
T cells escape thymic negative selection and
populate the peripheral lymphoid organs.
Unknown insults trigger b cell autoantigen shed-
ding into the milieu. Antigen-presenting cells
(APCs; e.g., DCs and/or B cells) then ferry these
autoantigens to the pancreatic LNs, where they
prime naı¨ve HA autoreactive CD4+ and CD8+
T cells. CD8+ T cells become activated upon
engaging cognate pMHC class I on autoantigen-
loaded APCs in the presence of HA autoreactive
CD4+ T helper cells, proinflammatory mediators
(IL-2 and other cytokines), and/or endogenous or
exogenous ‘‘danger signals.’’ These HA autoreac-
tive CD8+ and CD4+ T cells expand, differentiate
into CTLs, and migrate via the bloodstream into
pancreatic islets, where they effect b cell damage
through various means. FoxP3+CD4+CD25+ Treg
cells are recruited to the PLN (and islets) in
response to antigen and/or IL-2 and attempt to
suppress autoantigen presentation and T cell
activation. Upon chronic stimulation with cognate
pMHC, low-avidity (LA) autoreactive CD8+ T cells
differentiate into memory-like autoregulatory
CD8+ T cells and suppress the presentation of
autoantigens via a number of mechanisms, includ-
ing APC cytotoxicity. Current evidence suggests
that different T1D-associated genes encode
molecules (labeled in red) that target some of
these pathways.
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insulin and other tissue-specific antigens in mTECs, develop
an autoimmune polyendocrine syndrome (APS1 or APECED)
that often involves T1D. In this issue of Immunity, Husebye and
Anderson review this and other polyendocrine syndromes with
a focus on their T1D component, highlighting similarities and
differences with ‘‘conventional’’ T1D (Husebye and Anderson,
2010). A noteworthy similarity lies in the prevalence of anti-insulin
autoantibodies. In this light, it is tempting to speculate that the
INS VNTR modulates insulin expression by affecting the recruit-
ment of AIRE to INS. However, because AIRE has not been
linked to T1D risk in genome-wide association (GWA) studies
or in sequencing efforts aimed to identify rare variants (Nejentsev
et al., 2009) and because T1D is not normally associated with the
disorders that accompany APS1, it seems unlikely that intrinsic
variations in the expression or function of AIRE contribute to
T1D in non-APS1 patients.
CD8+ T Cells as Effectors and Suppressors
An important issue that these five reviews touch upon only very
briefly is the contribution of CD8+ T cells to T1D. There is now
widespread recognition that autoreactive CD8+ T cells play
a fundamental role in diabetogenesis (Tsai et al., 2008). Whether
recruitment of CD8+ T cells precedes, accompanies, or follows
that of CD4+ T cells and whether CD8+ T cells contributing to
disease initiation are insulin specific is unclear. A population of
CD8+ T cells recognizing an insulin-derived epitope (B:15–23)
appears in the islets of NOD mice as early as 3 weeks of age
(Wong et al., 1999), albeit in small numbers and accompanied
byamuch larger contingent ofCD8+Tcells of unknownspecificity438 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.(Amrani et al., 2000;Lieberman et al., 2004). The size of this pop-
ulationdeclinesquicklywithageand is replacedbyother specific-
ities, primarily a subset of CD8+ T cells that use CDR3-invariant
Va17+Ja42+ T cell receptors (TCRs) (Anderson et al., 1999;
DiLorenzo et al., 1998; Verdaguer et al., 1997; Verdaguer et al.,
1996). The latter target a peptide from islet-specific glucose-
6-phosphatase catalytic subunit-related protein (IGRP206–214)
(Lieberman et al., 2003) and are highly diabetogenic (Verdaguer
et al., 1996, 1997). Of note, these T cells are prevalent in blood,
particularly as clinical disease nears (Trudeau et al., 2003).
IGRP206–214 autoreactivity, however, is dispensable (Han et al.,
2005a; P.S. et al., unpublished data), presumably because islet-
associatedCD8+Tcells also recognizemanyother IGRPepitopes
(Han et al., 2005a), and epitopes on other, even non-b-cell-
specific, antigens (Lieberman et al., 2004). Also noteworthy is
the fact that, as T1D progresses, autoreactive CD8+ T cells
undergo a process of ‘‘avidity maturation’’ regulated by tolerance
and competition, whereby high-avidity CD8+ T cell clones gradu-
ally outcompete and replace their lower-avidity counterparts
(Amrani et al., 2000; Han et al., 2005b). Of interest, the latter
appear to actively suppress T1Dprogression (Amrani et al., 2000;
Han et al., 2005a). A similar T cell aviditymaturation response has
been described for glutamic acid decarboxylase (GAD)-specific
CD4+ T cells in human T1D (Ziegler and Nepom, 2010).
It is generally believed that autoreactive CD8+ T cells only
contribute to T1D by killing b cells. Recently, however, we
have found that chronic stimulation of naive low-avidity auto-
reactive CD8+ T cells by endogenous cognate epitopes triggers
their differentiation into memory-like autoregulatory T cells.
These memory low-avidity autoregulatory T cells suppress the
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the function of, and killing, autoantigen-loaded APCs and
therefore function as a negative feedback regulatory loop that
counters T1D progression (Tsai et al., 2010).
The identification of antigenic ligands for autoreactive CD8+
T cells in mice has inspired the search for similar specificities
in human blood and HLA-A2-transgenic mice. Although in one
of the accompanying reviews, Todd singles out a pre-proinsulin
peptide from a recent report (Skowera et al., 2008) as a link
between HLA class I, INS, and CD8+ T cell autoreactivity in T1D
(Todd, 2010), the picture emerging from all epitope-mapping
studies to date is far more complex, involving numerous
epitopes on several autoantigens, without any obvious hierarchy
of importance (Tsai et al., 2008).
The significance of increased frequencies of autoreactive
CD8+ T specificities in human blood samples is not clear. In
NOD mice, progression of insulitis to diabetes is invariably
accompanied by cyclic expansion of the circulating IGRP206–214-
reactive CD8+ T cell pool (Trudeau et al., 2003), suggesting that
events measurable in blood may provide information about
what is taking place in the target organ. Comparative studies of
peripheral blood mononuclear cells (PBMCs), lymphoid organs,
and pancreata fromdeceased humandiabetic patients, available
through the nPOD consortium (http://www.jdrfnpod.org), are
poised to help address this important issue.
T Cell Activation: Rules Governing Autoantigenicity
and Pathogenicity
b cells do not express costimulatory molecules or major histo-
compatibility complex (MHC) class II molecules and thus cannot
directly prime the diabetogenic autoimmune response. In addi-
tion, experimental evidence suggests that priming of both
CD4+ and CD8+ T cells occurs in the pancreatic lymph nodes
(PLNs) (Gagnerault et al., 2002; Ho¨glund et al., 1999; Zhang
et al., 2002). How b cell antigens come to be presented by
APCs in the PLNs and why certain antigens are preferred targets
of the diabetogenic T cell response is not known. Presentation of
b cell antigens does not appear to require a preceding CD8+
T cell attack on b cells (Yamanouchi et al., 2003) but probably
requires some sort of insult capable of triggering b cell antigen
shedding. The mode of shedding (as processed peptides, pep-
tides bound to chaperones, preformed peptide-MHC (pMHC)
complexes, or stable full-length antigens) and the type of b cell
insult (endoplasmic reticulum stress, apoptosis, necrosis, or
autophagy) may contribute to defining the autoantigenic hier-
archy in T1D. Antigens ‘‘concentrated’’ in apoptotic bodies or
b cell secretory granules may be shielded from degradation
and thus be able to gain access to APCs more efficiently. Inves-
tigating the consequences of these events on the activation of
naive T cells in models in which they can be triggered in a
synchronized manner should provide valuable clues. Adding to
the confusion is the fact that certain T cell responses occur
very efficiently yet exhibit low pathogenic potential and vice
versa, indicating that autoreactivity does not imply pathogenicity
(Burton et al., 2008). In fact, a recent computational biology
study suggests that pathogenicity peaks at low-to-moderate
amounts of autoantigenicity (P.S., A. Khadra, and L.-E. Keshet,
unpublished data). Another issue that deserves attention is the
nature of the endogenous ‘‘danger signals’’ that shift autoreac-tive T cell responses from tolerogenic to diabetogenic, such as
heat shock proteins, Toll-like receptor ligands, and uric acid
(Lang et al., 2005; Millar et al., 2003; Shi et al., 2006).
T Cell Recruitment
Upon recognition of cognate pMHC on DCs, T cells acquire the
ability to survey nonlymphoid tissues for the presence of their
cognate target antigens, with a preference for inflamed tissues
as well as tissues drained by the lymph nodes where activation
took place. It is generally thought that nonantigen-specific
inflammatory cues such as cytokines and chemokines can
recruit noncognate (i.e., bystander) T cells to inflamed islets.
Two recent studies in different experimental systems have
provided evidence against this view, namely that recruitment of
CD4+ and CD8+ T cells to islets is exquisitely antigen specific
(Lennon et al., 2009; P.S. et al., unpublished data). Accordingly,
the majority of T cells that are recruited to the pancreas in the
course of T1D are probably autoreactive. Whether this is also
true for T cells infiltrating human islets is not yet known.
Immune Dysregulation
Functional and numerical defects of invariant natural killer T
(iNKT) cells (reviewed in Novak et al., 2007) and FoxP3+CD4+
CD25+ T regulatory (Treg) cells have been described in NOD
mice (Gregori et al., 2003; Sgouroudis et al., 2008; Yamanouchi
et al., 2007). Treg cells suppress diabetogenic (and other) T cell
responses, at least in part, by targeting DCs (Serra et al., 2003).
In vivo, Treg cells preferentially interact with DCs, sparing
effector T cells (Tang et al., 2006). We find that NOD Treg cells
have suboptimal inhibitory effects on DCs (Yamanouchi et al.,
2007, 2010). Studies measuring the ability of Treg cells (or
TGFb) to suppress effector T cells in an APC-independent
manner (the most commonly used assay of Treg cell function)
have also suggested that the ‘‘Treg cell defect’’ in T1D involves
resistance of effector T cells to regulation (D’Alise et al., 2008;
Gregori et al., 2003; Schneider et al., 2008; You et al., 2005).
Although it is not known whether human T1D involves a defect
in the APC suppressive activity of Treg cells, a Treg cell-intrinsic
functional defect has been described in APS II patients (Kriegel
et al., 2004).
The FoxP3+ Treg cell subset may be a common target of
human T1D-associated genes. Although FOXP3 itself is not
associated with ‘‘conventional’’ T1D (Nejentsev et al., 2009),
patients with mutations in FOXP3 develop a syndrome that often
includes T1D (Husebye and Anderson, 2010). In addition to IL2
(encoding interleukin 2 [IL-2]) and IL2RA (encoding the high-
affinity receptor for IL-2), several other human T1D-associated
loci encode molecules that play a role in Treg cell development
and function, including CTLA4, PTPN22, and PTPN2. In fact,
defects in IL-2R signaling causing reduced maintenance of
FOXP3 expression, presumably encoded on several different
loci (including non-IL-2RA-linked such as PTPN2), have been
described in human T1D (Long et al., 2010).
Other Cellular Players
A significant number of other immune cell types are present in
the insulitic lesion, including NK and B cells. NK cells have
been implicated in T1D progression (Brauner et al., 2010; Poirot
et al., 2004), presumably by recognizing and killing b cells viaImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 439
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et al., 2009; Serreze et al., 1996), perhaps as an essential APC
type able to capture autoantigens (via surface Ig) and present
key pMHC complexes (Silveira et al., 2002). Two of the accom-
panying reviews highlight the significance of autoantibody
reactivity against islet antigens as markers of disease activity
(Stadinsky et al., 2010; Ziegler and Nepom, 2010). One issue
that is not discussed but is important to appreciate is that
most intra-islet B cells, at least in NOD mice, do not recognize
antigens targeted by islet-associated T cells or T1D-associated
antibodies. Rather, most of these intra-islet B cells recognize
antigens expressed exclusively by the peri-islet Schwann cell,
such as peripherin (Carrillo et al., 2005; Puertas et al., 2007).
Immune targeting of the pancreatic glia has been implicated in
the genesis of T1D (Tsui et al., 2008), and it is therefore possible
that these autoreactive B cells contribute to this process. It is not
currently known whether similar autoreactive B cell specificities
are present in human islet infiltrates.
Genes and Environment—Mechanisms
In an accompanying article, Todd provides an overview of the
genetics of T1D (Todd, 2010). Studies in humans and rodents
have shown that genetic susceptibility to T1D involves a small
number of genes with large effects and a larger number of genes
with significantly smaller contributions. Recent GWA studies
have uncovered more than 50 chromosomal regions carrying
risk variants for T1D (http://www.t1dbase.org). Todd points out
that more than 10 genes, most of them immunologically relevant,
can now be considered strong causal candidates, with the
caveat that long-range regulatory effects on other genes cannot
be excluded (Todd, 2010). Copy number variants and epigenetic
modifications of T1D-associated genes triggered by environ-
mental, metabolic, or inflammatory conditions are additional
areas of interest.
Notwithstanding the important contribution of genetics, a
‘‘perfect’’ combination of T1D-associated gene variants may
not be able to promote disease in the absence of appropriate
environmental factors. In fact, the concordance rate for T1D in
genetically identical twins is < 50%, and concordant twins can
develop disease at very different rates. At the population level,
it is also clear that T1D is not a ‘‘one size fits all.’’ The rate of
disease progression in affected individuals is uneven; in some
very young patients who do not have monogenic (neonatal)
forms of diabetes, the autoimmune process progresses very
rapidly; others show signs of autoimmunity long before hypergly-
cemia appears; others develop what appears to be autoimmune
diabetes without any signs of anti-islet autoimmunity (i.e., auto-
antibodies); and others display such signs but never progress to
clinical disease (Ziegler and Nepom, 2010). Whether such differ-
ences in the rates of disease progression exist because some
patients canmount forms of adaptive immunoregulation capable
of muting disease progression or because their b cells have
unusual replicative capacity, or because of a combination of
these and other factors, is unclear.
Understanding the biology underpinning these different gene
environment-T1D associations is essential to fully comprehend
the pathogenesis of T1D, to identify targets for effective
therapeutic intervention, and to help understand its clinical
heterogeneity. Unfortunately, the status of this understanding440 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.is rudimentary. In addition, most of the environmental variables
and/or insults that affect the penetrance of T1D-associated
genes remain largely hypothetical, although there are some
intriguing clues. For example, human T1D-associated loci
include the ‘‘interferon-induced with helicase C domain 1’’
gene (IFIH1) and the TLR7-TLR8 region, which encode sensors
of viral RNA (Todd, 2010). The null form of IFIH1 affords resis-
tance (Todd, 2010), suggesting that its wild-type counterpart
contributes to T1D by sensing viral triggers, possibly enterovi-
ruses (Knip et al., 2005). Alterations in the gut microflora are
also thought to play a role, albeit through poorly understood
mechanisms (Wen et al., 2008).
A useful discussion onmechanisms underlying different gene-
T1D associations warrants a brief overview on the genetics
of human T1D, reviewed in depth (highlighting common and
divergent associations with other autoimmune disorders) by
Todd (Todd, 2010). In addition to INS, the most important gene
region comprises the HLA loci, which affords 40%–50% of
the T1D risk. Human T1D is primarily associated with HLA-
DRB1 and -DQB1, although class I genes also play key roles.
DQB1 alleles encoding DQb chains carrying Ser, Ala, or Val at
position 57 provide risk, whereas those encoding DQb chains
with Asp at this position afford protection. Susceptibility I-A
(in mice) and DQ molecules (in humans) have unusual peptide-
binding pockets (Corper et al., 2000; Stratmann et al., 2000)
and presumably afford T1D susceptibility by presenting a unique
set of peptides. CTLA4, which encodes a negative regulator of
T cell function (cytotoxic T-lymphocyte antigen 4 [CTLA-4]), is
also associated with T1D. The susceptibility allele generates
reduced amounts of a splice variant that encodes the soluble
form of CTLA-4, and this has been correlated with variations in
the biology of Treg cells, which constitutively express CTLA-4
(Atabani et al., 2005). PTPN22, encoding lymphoid tyrosine-
phosphatase (LYP, a negative regulator of T cell activation),
is associated with several autoimmune diseases, including
T1D. Notably, the T1D-associated polymorphism abolishes
the binding of the negative regulatory kinase CSK and, conse-
quently, results in increased LYP activity and enhanced suppres-
sion of T cell signaling. Although this may seem counterintuitive
(suppression of T cell signaling should inhibit, rather than
promote autoimmunity), the gain-of-function variant of PTPN22
may impair negative selection of autoreactive T cells and inhibit
Treg cell development (Vang et al., 2005). A related gene is
PTPN2, encoding a tyrosine phosphatase that is also a negative
regulator of T cell activation and participates in IL-2R signaling.
IL2 and IL2RA, discussed below, are two other genes that
have been convincingly associated with T1D (Todd, 2010).
In their review, Husebye and Anderson note that the highest
genetic risk for patients affected with APS II (developing two of
the following: T1D, Addison’s disease, or autoimmune thyroid
disease) maps to the HLA, CTLA4, and PTPN22 loci (Husebye
and Anderson, 2010). Whether the associated alleles are the
same as those found in ‘‘conventional’’ T1D is unclear. In this
regard, an important notion raised by Todd is that, although
T1D shares a number of disease-associated loci with other auto-
immune disorders, including inflammatory bowel disease, rheu-
matoid arthritis, and multiple sclerosis, the associated SNPs are
not always the same, and the effects of shared alleles on disease
susceptibility can be the opposite (Todd, 2010). It is thus likely
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permissive for the diseases they develop.
Modeling MHC-Linked Genetic Susceptibility
or Resistance in Mice
The plethora of T1D-associated yet common allelic variants may
afford diabetes risk by targeting a few key biological pathways.
Marked dysregulation of a pathogenic pathway in a patient
may involve the cumulative effects of multiple ‘‘hits,’’ each
encoded on a different locus, at different steps in that same
pathway (Figure 1). This ‘‘pathway’’ hypothesis would explain
why most patients would only share subsets of T1D-associated
variants. Unfortunately, dissecting the mechanisms of action of
each of these rather subtle and ‘‘normal’’ genetic polymorphisms
independently of the effects of other loci is not a trivial pursuit.
Fortunately, however, some of these human gene-T1D associa-
tions also promote T1D in themouse. Analyses of congenic NOD
mice have confirmed the existence of > 20 T1D-associated (Idd)
loci (Maier and Wicker, 2005). The nature of the genes respon-
sible has been resolved for only a handful of regions, including
Idd1-MHC (Vyse and Todd, 1996), Idd16-b2m (Hamilton-
Williams et al., 2001), Idd4.1-Trpv1 (Razavi et al., 2006), Idd3-
Il2 (Yamanouchi et al., 2007), Idd5.1-Ctla4 (Wicker et al., 2004),
and Idd5.2-Nramp1 (Kissler et al., 2006). It is quite remarkable
that T1D susceptibility in humans and mice is modulated by
polymorphisms in similar gene pathways, such as IL-2-IL-2RA,
CTLA-4, andMHC. These shared associations offer the opportu-
nity to understand mechanisms. But even for human genes
that are not associated with T1D susceptibility in mice, murine
models can be developed to mimic the corresponding genetic
alterations (i.e., expression differences). Below, I focus on pos-
sible mechanisms underlying the associations between T1D
and MHC class II or the IL-2-IL-2R pathway, learned through
studies of genetically manipulated NOD mice.
How do MHC class II variants afford T1D susceptibility or
resistance? Stadinsky et al. propose that the loss of tolerance
to diabetogenic autoantigens relates to the manner in which
specific peptides bind to susceptibility MHC class II molecules
and to the way these pMHC complexes are recognized by
cognate TCRs (Stadinsky et al., 2010). I propose that a full
understanding of MHC-autoimmune disease associations would
benefit, also, from addressing an equally important question:
how do certain alleles afford dominant resistance? It is my
contention that both susceptibility and protection hinge on the
same mechanism.
The NOD mouse is homozygous for a unique H-2 haplotype
that carries a nonproductive I-Ea gene and encodes an I-Aad/
bg7 heterodimer in which the His and Asp found at positions 56
and 57 in most I-Ab chains (the murine equivalent of DQb) are
replaced by Pro and Ser, respectively. Whereas I-Ag7 promotes
T1D by presenting a distinct set of peptides owing to unique
properties of its peptide-binding pockets (Corper et al., 2000;
Stratmann et al., 2000), studies of NOD mice expressing non-
NOD MHC haplotypes or transgenes have proven that class II
molecules can also afford dominant resistance (Tisch and
McDevitt, 1996). Studies in NODmice expressing a highly diabe-
togenic I-Ag7-restricted TCR (4.1) showed that thymocytes
expressing this TCR undergo deletion in a number of H-2g7/x
heterozygous and MHC-transgenic NOD mice by engaginganti-T1D class II molecules on hematopoietic APCs (Schmidt
et al., 1997, 1999; Thiessen et al., 2002). These observations
raised the possibility that protective class II molecules afford
T1D resistance by targeting TCRs that engage diabetogenic
pMHC class II complexes in a unique manner, one that would
render some of these TCRs promiscuous for MHC (Schmidt
et al., 1997, 1999; Thiessen et al., 2002). This mechanism may
account for the outcome of a similar study in transgenic mice
expressing HLA-A2 or -A3 molecules and an encephalitogenic
TCR, which triggered disease in the context of HLA-A3 but
underwent tolerance in the context of HLA-A2 (Friese et al.,
2008). Thus, MHC promiscuity (ability to engage more than
one MHC molecule) may be a feature of certain highly patho-
genic (including perhaps some of the key) autoreactive T cell
specificities (Schmidt et al., 1997).
Intriguingly, structural studies of five different autoreactive
TCRs (unrelated to T1D) have revealed that they either bind their
cognate pMHC ligands with a different topology than foreign
antigen-specific TCRs or recognize a peptide that only partially
occupies the peptide-binding groove of the MHC molecule
(Wucherpfennig et al., 2009). These TCRs make substantially
fewer contacts with peptide residues than conventional TCRs
(Wucherpfennig et al., 2009). It is therefore possible that the
proposed relationship between MHC promiscuity and pathoge-
nicity for T1D-relevant TCRs is related to such an alteredmode of
binding, whereby polymorphicMHC residues on protectiveMHC
class II compensate for the paucity of TCR-peptide and/or I-Ag7
molecular contacts. As proposed by Stadinsky et al., these
unusual modes of binding of peptides to I-Ag7 may enable the
corresponding autoreactive T cell specificities to evade thymic
negative selection (Stadinsky et al., 2010), an idea that is
compatible with our ‘‘promiscuity’’ hypothesis (Schmidt et al.,
1997). In the periphery (i.e., islets and/or PLNs), these interme-
diate- to low-avidity T cells (from the thymus perspective) may
transition into a higher-avidity diabetogenic state by recognizing
posttranslationally modified (or high concentrations of unmodi-
fied) cognate autoantigens, particularly in the presence of
endogenous adjuvants. Certain features of known T1D-relevant
TCRs point to the existence of such pMHC-recognition anoma-
lies. For example, nearly all IGRP206–214-reactive TCRs use iden-
tical TCRa chains (including their CDR3a regions), suggesting
that they primarily contact peptide residues via their invariant
TCRa chain (Anderson et al., 1999; Han et al., 2005b). The
BDC2.5-TCR may be another example of this, as it recognizes
a chromogranin A-derived peptide that binds to the I-Ag7 mole-
cule in a very unusual fashion (Stadinski et al., 2010). Likewise,
most B:9–23-specific TCRs use a rather conserved TCRa chain
(Stadinsky et al., 2010), and the insulin B:9–23-I-Ag7 complex
targeted by ‘‘type B’’ insulin-reactive CD4+ T cell clones presum-
ably exists at a unique conformation (Mohan et al., 2010).
Whether this hypothetical paradigm applies to human DR-DQ
molecules positively (i.e., DR3-DQ2 and DR4-DQ8) and nega-
tively associated (i.e., DQ6) with T1D is not known.
Modeling Non-MHC-Linked Genetic Susceptibility
or Resistance in Mice
Given the smaller independent contribution of non-MHC-linked
genes to T1D susceptibility and/or resistance, dissecting the
underlying mechanisms of action remains a major challenge.Immunity 32, April 23, 2010 ª2010 Elsevier Inc. 441
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cellular pathways for T1D in humans and rodents makes it likely
that manipulation of the mouse orthologs of human T1D genes
will affect the T1D response. Because disease-associated vari-
ants at known T1D loci are generally common alleles encoding
small differences in expression and/or function, one approach
to unravel mechanisms of action is to define the consequences
of expression variation of the mouse orthologs of these genes.
Mechanistic studies on the murine Il2-Il21 region provide an
example of how studies in mice can shed light into mechanisms
underlying similar gene-disease associations in humans (i.e.,
the human IL2-IL21 region and/or IL2RA). A region on mouse
chromosome 3, Idd3, containing the genes for IL-2 and
IL-21, is associated with T1D. Protective Idd3 alleles transcribe
2-fold higher amounts of IL-2 mRNA (but comparable amounts
of IL-21 mRNA) than their susceptibility counterparts (Yamanou-
chi et al., 2007). Although there is also allelic variation in IL-21
expression among different strains (McGuire et al., 2009; Yama-
nouchi et al., 2007), this variation (and the putative SNPs
accounting for it) is not disease associated (i.e., differences in
expression of alleles do not correlate with their association
with susceptibility or resistance) (Yamanouchi et al., 2007). In
vivo, the increased transcriptional activity of protective Idd3
alleles translated into higher amounts of IL-2 production by
autoreactive T cells and into enhanced development and func-
tion of Treg cells (Yamanouchi et al., 2007), observations that
were extended upon by others (Kamanaka et al., 2009; Sgourou-
dis et al., 2008; Tang et al., 2008). The role for Il2 was demon-
strated genetically by introducing an Il2 null allele into NOD
mice carrying one copy of a protective Idd3 allele (hence,
reducing the IL-2 production competency of T cells to amounts
similar to those seen in wild-type NOD mice without affecting
IL-21 expression). Accordingly, the NOD haplotype of Il2 SNPs
predisposes to autoimmunity by reducing IL-2 production from
effector T cells and impairing a negative feedback mechanism
that fosters Treg cell activity and recruitment, DC suppression,
and inhibition of autoantigen presentation (Figure 1).
In humans, the IL2-IL21 region is also associated with several
human autoimmune disorders (Todd, 2010). However, as Todd
points out, the association of this region with different autoim-
mune diseases is not with the same SNPs. Whereas the IL2-
IL21SNP that ismost strongly associatedwith T1D lies in the first
exon of IL2, other autoimmune diseases associated with this
region may be linked to IL21 instead (Todd, 2010). Although
IL-21 expression is necessary for murine T1D (Spolski et al.,
2008; Sutherland et al., 2009), IL-21R signaling does not appear
to be rate limiting for disease (Spolski et al., 2008; Sutherland
et al., 2009), and an IL21 allele that encodes higher amounts of
IL-21 does not afford human T1D risk (Todd, 2010). A functionally
related but unlinked locus, IL2RA, encoding the IL-2Ra chain
(CD25) is strongly associated with human T1D (Vella et al.,
2005). Of interest, human IL2RA-linked T1D susceptibility segre-
gates with an 30%–50% decrease in the expression of CD25
pre-mRNA and surface protein on activated-memory T cells
and, to a lesser extent, Treg cells (Dendrou et al., 2009). Of
note, lower expression of CD25 in memory T cells from individ-
uals with IL2RA susceptibility genotypes is associated with lower
IL-2 secretion, which might synergize with lower expression of
CD25 on Treg cells to impair Treg cell function (Dendrou et al.,442 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.2009). Because IL-2R signaling plays a key role in Treg cell
biology (Malek, 2008) and both the murine Il2- and human
IL2RA-T1D associations correlate with reduced expression of
Il2 and IL2RA, respectively, they may both operate by impairing
Treg cell development or function.
Another area of inquiry where animal models are of essential
value is the investigation of the cellular and tissue ‘‘anatomy’’
of T1D-associated gene variation. Typically, non-MHC genes
linked to T1D code for proteins expressed in numerous cell
types. For example, the cellular source of the IL-2 that promotes
Treg cell homeostasis is unclear. Likewise, it will be important to
exclude an effect of the T1D-associated IL2RA expression
phenotype on T1D via CD25-expressing cell types other than
memory CD4+ T cells or Tregs, such as DCs, monocytes, B cells,
or NK cells.
‘‘Conquering’’ T1D—Prevention and Therapy
In addition to helping understand mechanisms of disease, gene
variability associated with T1D may have predictive value.
However, because most genes afford small effects and there is
significant heterogeneity, Todd argues that genetics alone,
with the exception of HLA, will not be useful for disease predic-
tion (Todd, 2010). At the other end of the spectrum lies autoanti-
body reactivity against insulin, GAD65, insulinoma-associated 2
(IA-2), and/or zinc transporter 8 (ZnT8), which has very high
predictive value (Stadinsky et al., 2010; Ziegler and Nepom,
2010). Ziegler and Nepom suggest that pMHC tetramers may
help delineate a transition from high preclinical risk to active
disease on the basis of substantial accumulation of high-avidity
memory effector cells (Ziegler and Nepom, 2010). However, the
sensitivity and specificity of current pMHC tetramer-based
assays is low (Herold et al., 2009). Sensitive and specific predic-
tion tools will be of the essence when effective and safe immuno-
therapies become available.
The complexity of the diabetogenic autoimmune response is
a barrier to the design of therapies that can blunt autoreactivity
without impairing systemic immunity. Although nonantigen-
specific mAb-based approaches, such as anti-CD3 (Herold
et al., 2002; Keymeulen et al., 2005) and anti-CD20 (Pescovitz
et al., 2009), have shown benefit in clinical trials, these strategies
bear the risk of compromising systemic immunity, particularly if
long-term efficacy requires continued therapy. A comprehensive
list of other nonantigen-specific approaches currently in clinical
trials can be found at http://diabetesplan.niddk.nih.gov. In their
accompanying review article, Luo et al. argue that approaches
capable of selectively inducing b cell tolerance may be the
most desirable (Luo et al., 2010). Meeting this need will be
a daunting task because diabetogenesis is both cellularly and
antigenically complex. With regards to antigen-specific thera-
pies, immunization with GAD in alum has been shown to delay
the progression of c-peptide loss (a surrogate marker of pancre-
atic insulin production) in new onset diabetic individuals
(Ludvigsson et al., 2008). Another approach currently under
investigation involves intramuscular injections of antigen-encod-
ing DNA vaccines (Solvason et al., 2008). A fundamental short-
coming of these strategies lies in the incomplete understanding
of mechanisms of action.
Alternatives include the use of soluble peptides or antigen-
loaded ethylene-carbodiimide (ECDI)-fixed PBMCs to induce
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ever, unless they are tailored to eliminate key autoantigenic
specificities at the right time (i.e., insulin-specific T cells before
other specificities become involved) or operate by eliciting
disease-suppressive Treg cells, these approaches may not be
successful. Other potential avenues include the transfer of
antigen-specific Treg cells or peptide-loaded immature DCs
(to elicit antigen-specific Treg cell responses). Limitations of
these cell transfer strategies include their cost and limited com-
mercial value.
Noncell-transfer-based strategies capable of inducing or
boosting antigen-specific immunoregulation in vivo should be
able overcome the limitations of cellular therapy. Vitamin D3,
for example, has immunoregulatory properties in mice (Gregori
et al., 2002). Peptide-conjugated anti-DEC201 mAbs have
been used in rodents to selectively deliver autoantigenic pep-
tides to immature DCs and tolerize cognate autoreactive
T cells (Mukhopadhaya et al., 2008). This strategy has the
potential to induce antigen-specific immunoregulation. Another
avenue is the local delivery of immunomodulatory molecules to
the pancreas via, for example, microparticles (Phillips et al.,
2008). More recently, we have shown that systemic delivery of
disease-relevant pMHC complexes coated onto nanoparticles
can restore normoglycemia in diabetic NOD mice (Tsai et al.,
2010). These pMHC-coated nanoparticles selectively expand
a new type of memory-like antigen-specific autoregulatory
CD8+ T cells that arise spontaneously during disease progres-
sion from naive low-avidity autoreactive T cells and afford
disease-specific immunosuppression. Because these pools of
protective antigen-experienced T cells are not limited to specific
epitopes or autoantigens and arise only in affected individuals,
they are attractive new targets for therapeutic intervention.
Concluding Remarks
The availability of therapies that can revert hyperglycemia in
newly diagnosed diabetic NOD mice and delay c-peptide loss
in new onset patients demonstrates that the functional b cell
mass at the onset of T1D in both mice and humans is not inexo-
rably lost. However, whether immunotherapies capable of
restoring normoglycemia do so by enabling b cell regeneration
and/or replication or by promoting functional recovery of residual
b cells is unclear (Ogawa et al., 2004; Phillips et al., 2007;
Sherry et al., 2007). Also, it would be interesting to determine
whether the replicative and regenerative b cell response of the
‘‘postinsulitic’’ pancreas is impaired as compared to that seen
in nonimmune-mediated models of b cell ablation, wherein
b cell replication is extensive (Nir et al., 2007). We can consider
two possibilities: (1) the b cell regenerative and/or replicative
capacity of the diabetic pancreas is intrinsically low (i.e., is
a genetic trait) or (2) is similar to that of nonautoimmune-prone
individuals but is induced only in response to acute signals
(sudden b cell loss) or becomes muted upon chronic islet inflam-
mation. The NODmodel is uniquely suited to study the contribu-
tion of b and non-b cells as sources of regeneration in T1D (under
autoimmune pressure) and after immune intervention leading to
reversal of hyperglycemia. Resolving this issue is important
because induction of b cell regeneration, together with abroga-
tion of autoimmunity, could potentially form part of future treat-
ments to cure T1D.In sum, it is now clear that T1D is caused by an overwhelmingly
complex autoimmune process that is triggered by ill-defined
environmental factors in permissive genetic backgrounds.
A constellation of gene variants scattered throughout the
genome, generally operating via relatively small changes in
expression and/or function, provides the code, scripting a care-
fully orchestrated series of immune events that involve virtually
every cell type of the immune system and eventually culminate
in near complete loss of b cells. Understanding this complexity
is essential in the quest for a cure. Modeling human T1D-relevant
gene variation in rodents and interrogating in humans the
paradigms brought forth by these studies are likely to pinpoint
new targets for therapeutic intervention. Studies in NOD mice
(and humanized murine models) will continue to be essential in
providing proof-of-concept and guidance.ACKNOWLEDGMENTS
I acknowledge funding from the Canadian Institutes of Health Research, the
Natural Sciences and Engineering Research Council of Canada, and the
Juvenile Diabetes Research Foundation. P.S. is a Scientist of Alberta Inno-
vates-Health Solutions (formerly AHFMR) and a JDRF Scholar. I gratefully
acknowledge the many scientific and intellectual contributions of past and
present laboratory members and collaborators. I apologize to those authors
whose publications could not be cited owing to space constraints. The
JMDRC is supported by the Diabetes Association (Foothills).
REFERENCES
Amrani, A., Verdaguer, J., Serra, P., Tafuro, S., Tan, R., and Santamaria, P.
(2000). Nature 406, 739–742.
Anderson, B., Park, B.J., Verdaguer, J., Amrani, A., and Santamaria, P. (1999).
Proc. Natl. Acad. Sci. USA 96, 9311–9316.
Atabani, S.F., Thio, C.L., Divanovic, S., Trompette, A., Belkaid, Y., Thomas,
D.L., and Karp, C.L. (2005). Eur. J. Immunol. 35, 2157–2162.
Bennett, S.T., Lucassen, A.M., Gough, S.C., Powell, E.E., Undlien, D.E.,
Pritchard, L.E., Merriman, M.E., Kawaguchi, Y., Dronsfield, M.J., Pociot, F.,
et al. (1995). Nat. Genet. 9, 284–292.
Brauner, H., Elemans, M., Lemos, S., Broberger, C., Holmberg, D., Flodstro¨m-
Tullberg, M., Ka¨rre, K., and Ho¨glund, P. (2010). J. Immunol. 184, 2272–2280.
Burton, A.R., Vincent, E., Arnold, P.Y., Lennon, G.P., Smeltzer, M., Li, C.S.,
Haskins, K., Hutton, J., Tisch, R.M., Sercarz, E.E., et al. (2008). Diabetes 57,
1321–1330.
Carrillo, J., Puertas, M.C., Alba, A., Ampudia, R.M., Pastor, X., Planas, R.,
Riutort, N., Alonso, N., Pujol-Borrell, R., Santamaria, P., et al. (2005). Diabetes
54, 69–77.
Corper, A.L., Stratmann, T., Apostolopoulos, V., Scott, C.A., Garcia, K.C.,
Kang, A.S., Wilson, I.A., and Teyton, L. (2000). Science 288, 505–511.
D’Alise, A.M., Auyeung, V., Feuerer, M., Nishio, J., Fontenot, J., Benoist, C.,
and Mathis, D. (2008). Proc. Natl. Acad. Sci. USA 105, 19857–19862.
Dendrou, C.A., Plagnol, V., Fung, E., Yang, J.H., Downes, K., Cooper, J.D.,
Nutland, S., Coleman, G., Himsworth, M., Hardy, M., et al. (2009). Nat. Genet.
41, 1011–1015.
DiLorenzo, T.P., Graser, R.T., Ono, T., Christianson, G.J., Chapman, H.D.,
Roopenian, D.C., Nathenson, S.G., and Serreze, D.V. (1998). Proc. Natl.
Acad. Sci. USA 95, 12538–12543.
Fan, Y., Rudert, W.A., Grupillo, M., He, J., Sisino, G., and Trucco, M. (2009).
EMBO J. 28, 2812–2824.
French, M.B., Allison, J., Cram, D.S., Thomas, H.E., Dempsey-Collier, M.,
Silva, A., Georgiou, H.M., Kay, T.W., Harrison, L.C., and Lew, A.M. (1997).
Diabetes 46, 34–39.Immunity 32, April 23, 2010 ª2010 Elsevier Inc. 443
Immunity
PerspectiveFriese, M.A., Jakobsen, K.B., Friis, L., Etzensperger, R., Craner, M.J.,
McMahon, R.M., Jensen, L.T., Huygelen, V., Jones, E.Y., Bell, J.I., and
Fugger, L. (2008). Nat. Med. 14, 1227–1235.
Gagnerault, M.C., Luan, J.J., Lotton, C., and Lepault, F. (2002). J. Exp. Med.
196, 369–377.
Gregori, S., Giarratana, N., Smiroldo, S., Uskokovic, M., and Adorini, L. (2002).
Diabetes 51, 1367–1374.
Gregori, S., Giarratana, N., Smiroldo, S., and Adorini, L. (2003). J. Immunol.
171, 4040–4047.
Gur, C., Porgador, A., Elboim, M., Gazit, R., Mizrahi, S., Stern-Ginossar, N.,
Achdout, H., Ghadially, H., Dor, Y., Nir, T., et al. (2010). Nat. Immunol. 11,
121–128.
Hamilton-Williams, E.E., Serreze, D.V., Charlton, B., Johnson, E.A., Marron,
M.P., Mullbacher, A., and Slattery, R.M. (2001). Proc. Natl. Acad. Sci. USA
98, 11533–11538.
Han, B., Serra, P., Amrani, A., Yamanouchi, J., Mare´e, A.F., Edelstein-Keshet,
L., and Santamaria, P. (2005a). Nat. Med. 11, 645–652.
Han, B., Serra, P., Yamanouchi, J., Amrani, A., Elliott, J.F., Dickie, P.,
Dilorenzo, T.P., and Santamaria, P. (2005b). J. Clin. Invest. 115, 1879–1887.
Herold, K.C., Hagopian, W., Auger, J.A., Poumian-Ruiz, E., Taylor, L.,
Donaldson, D., Gitelman, S.E., Harlan, D.M., Xu, D., Zivin, R.A., and Bluestone,
J.A. (2002). N. Engl. J. Med. 346, 1692–1698.
Herold, K.C., Brooks-Worrell, B., Palmer, J., Dosch, H.M., Peakman, M.,
Gottlieb, P., Reijonen, H., Arif, S., Spain, L.M., Thompson, C., Lachin,
J.M.Type 1 Diabetes TrialNet Research Group. (2009). Diabetes 58,
2588–2595.
Ho¨glund, P., Mintern, J., Waltzinger, C., Heath, W., Benoist, C., and Mathis, D.
(1999). J. Exp. Med. 189, 331–339.
Husebye, E.S., and Anderson, M.S. (2010). Immunity 32, this issue, 479–487.
Jaeckel, E., Lipes, M.A., and von Boehmer, H. (2004). Nat. Immunol. 5,
1028–1035.
Kamanaka, M., Rainbow, D., Schuster-Gossler, K., Eynon, E.E., Chervonsky,
A.V., Wicker, L.S., and Flavell, R.A. (2009). Proc. Natl. Acad. Sci. USA 106,
11236–11240.
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A.G., Mathieu, C., Kaufman,
L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005).
N. Engl. J. Med. 352, 2598–2608.
Kissler, S., Stern, P., Takahashi, K., Hunter, K., Peterson, L.B., and Wicker,
L.S. (2006). Nat. Genet. 38, 479–483.
Knip, M., Veijola, R., Virtanen, S.M., Hyo¨ty, H., Vaarala, O., and Akerblom, H.K.
(2005). Diabetes 54 (Suppl 2), S125–S136.
Kriegel, M.A., Lohmann, T., Gabler, C., Blank, N., Kalden, J.R., and Lorenz,
H.M. (2004). J. Exp. Med. 199, 1285–1291.
Krishnamurthy, B., Dudek, N.L., McKenzie, M.D., Purcell, A.W., Brooks, A.G.,
Gellert, S., Colman, P.G., Harrison, L.C., Lew, A.M., Thomas, H.E., and Kay,
T.W. (2006). J. Clin. Invest. 116, 3258–3265.
Lang, K.S., Recher, M., Junt, T., Navarini, A.A., Harris, N.L., Freigang, S.,
Odermatt, B., Conrad, C., Ittner, L.M., Bauer, S., et al. (2005). Nat. Med. 11,
138–145.
Lennon, G.P., Bettini, M., Burton, A.R., Vincent, E., Arnold, P.Y., Santamaria,
P., and Vignali, D.A. (2009). Immunity 31, 643–653.
Lieberman, S.M., and DiLorenzo, T.P. (2003). Tissue Antigens 62, 359–377.
Lieberman, S.M., Evans, A.M., Han, B., Takaki, T., Vinnitskaya, Y., Caldwell,
J.A., Serreze, D.V., Shabanowitz, J., Hunt, D.F., Nathenson, S.G., et al.
(2003). Proc. Natl. Acad. Sci. USA 100, 8384–8388.
Lieberman, S.M., Takaki, T., Han, B., Santamaria, P., Serreze, D.V., and
DiLorenzo, T.P. (2004). J. Immunol. 173, 6727–6734.444 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.Long, S.A., Cerosaletti, K., Bollyky, P.L., Tatum, M., Shilling, H., Zhang, S.,
Zhang, Z.Y., Pihoker, C., Sanda, S., Greenbaum, C., and Buckner, J.H.
(2010). Diabetes 59, 407–415.
Ludvigsson, J., Faresjo¨, M., Hjorth, M., Axelsson, S., Che´ramy, M., Pihl, M.,
Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008). N.
Engl. J. Med. 359, 1909–1920.
Luo, X., Herold, K.C., and Miller, S.D. (2010). Immunity 32, this issue, 488–499.
Maier, L.M., and Wicker, L.S. (2005). Curr. Opin. Immunol. 17, 601–608.
Malek, T.R. (2008). Annu. Rev. Immunol. 26, 453–479.
McGuire, H.M., Vogelzang, A., Hill, N., Flodstro¨m-Tullberg, M., Sprent, J., and
King, C. (2009). Proc. Natl. Acad. Sci. USA 106, 19438–19443.
Millar, D.G., Garza, K.M., Odermatt, B., Elford, A.R., Ono, N., Li, Z., and
Ohashi, P.S. (2003). Nat. Med. 9, 1469–1476.
Miller, S.D.,Wetzig, R.P., and Claman, H.N. (1979). J. Exp. Med. 149, 758–773.
Mohan, J.F., Levisetti, M.G., Calderon, B., Herzog, J.W., Petzold, S.J., and
Unanue, E.R. (2010). Nat. Immunol. 11, 350–354.
Mukhopadhaya, A., Hanafusa, T., Jarchum, I., Chen, Y.G., Iwai, Y., Serreze,
D.V., Steinman, R.M., Tarbell, K.V., and DiLorenzo, T.P. (2008). Proc. Natl.
Acad. Sci. USA 105, 6374–6379.
Nakayama, M., Abiru, N., Moriyama, H., Babaya, N., Liu, E., Miao, D., Yu, L.,
Wegmann, D.R., Hutton, J.C., Elliott, J.F., and Eisenbarth, G.S. (2005). Nature
435, 220–223.
Nejentsev, S., Walker, N., Riches, D., Egholm, M., and Todd, J.A. (2009).
Science 324, 387–389.
Nir, T., Melton, D.A., and Dor, Y. (2007). J. Clin. Invest. 117, 2553–2561.
Novak, J., Griseri, T., Beaudoin, L., and Lehuen, A. (2007). Int. Rev. Immunol.
26, 49–72.
Ogawa, N., List, J.F., Habener, J.F., and Maki, T. (2004). Diabetes 53,
1700–1705.
Pescovitz, M.D., Greenbaum, C.J., Krause-Steinrauf, H., Becker, D.J.,
Gitelman, S.E., Goland, R., Gottlieb, P.A., Marks, J.B., McGee, P.F., Moran,
A.M., et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. (2009).
N. Engl. J. Med. 361, 2143–2152.
Phillips, J.M., O’Reilly, L., Bland, C., Foulis, A.K., and Cooke, A. (2007).
Diabetes 56, 634–640.
Phillips, B., Nylander, K., Harnaha, J., Machen, J., Lakomy, R., Styche, A.,
Gillis, K., Brown, L., Lafreniere, D., Gallo, M., et al. (2008). Diabetes 57,
1544–1555.
Poirot, L., Benoist, C., and Mathis, D. (2004). Proc. Natl. Acad. Sci. USA 101,
8102–8107.
Puertas, M.C., Carrillo, J., Pastor, X., Ampudia, R.M., Planas, R., Alba, A.,
Bruno, R., Pujol-Borrell, R., Estanyol, J.M., Vives-Pi, M., and Verdaguer, J.
(2007). J. Immunol. 178, 6533–6539.
Razavi, R., Chan, Y., Afifiyan, F.N., Liu, X.J., Wan, X., Yantha, J., Tsui, H., Tang,
L., Tsai, S., Santamaria, P., et al. (2006). Cell 127, 1123–1135.
Schmidt, D., Verdaguer, J., Averill, N., and Santamaria, P. (1997). J. Exp. Med.
186, 1059–1075.
Schmidt, D., Amrani, A., Verdaguer, J., Bou, S., and Santamaria, P. (1999).
J. Immunol. 162, 4627–4636.
Schneider, A., Rieck, M., Sanda, S., Pihoker, C., Greenbaum, C., and Buckner,
J.H. (2008). J. Immunol. 181, 7350–7355.
Serra, P., Amrani, A., Yamanouchi, J., Han, B., Thiessen, S., Utsugi, T.,
Verdaguer, J., and Santamaria, P. (2003). Immunity 19, 877–889.
Serreze, D.V., Chapman, H.D., Varnum, D.S., Hanson, M.S., Reifsnyder, P.C.,
Richard, S.D., Fleming, S.A., Leiter, E.H., and Shultz, L.D. (1996). J. Exp. Med.
184, 2049–2053.
Sgouroudis, E., Albanese, A., and Piccirillo, C.A. (2008). J. Immunol. 181,
6283–6292.
Immunity
PerspectiveSherry, N.A., Chen, W., Kushner, J.A., Glandt, M., Tang, Q., Tsai, S., Santama-
ria, P., Bluestone, J.A., Brillantes, A.M., and Herold, K.C. (2007). Endocri-
nology 148, 5136–5144.
Shi, Y., Galusha, S.A., and Rock, K.L. (2006). J. Immunol. 176, 3905–3908.
Silveira, P.A., Johnson, E., Chapman, H.D., Bui, T., Tisch, R.M., and Serreze,
D.V. (2002). Eur. J. Immunol. 32, 3657–3666.
Skowera, A., Ellis, R.J., Varela-Calvin˜o, R., Arif, S., Huang, G.C., Van-Krinks,
C., Zaremba, A., Rackham, C., Allen, J.S., Tree, T.I., et al. (2008). J. Clin. Invest.
118, 3390–3402.
Solvason, N., Lou, Y.P., Peters, W., Evans, E., Martinez, J., Ramirez, U.,
Ocampo, A., Yun, R., Ahmad, S., Liu, E., et al. (2008). J. Immunol. 181,
8298–8307.
Spolski, R., Kashyap, M., Robinson, C., Yu, Z., and Leonard,W.J. (2008). Proc.
Natl. Acad. Sci. USA 105, 14028–14033.
Stadinski, B.D., Delong, T., Reisdorph, N., Reisdorph, R., Powell, R.L.,
Armstrong, M., Piganelli, J.D., Barbour, G., Bradley, B., Crawford, F., et al.
(2010). Nat. Immunol. 11, 225–231.
Stadinsky, B., Kappler, J., and Eisenbarth, G.S. (2010). Immunity 32, this issue,
446–456.
Stratmann, T., Apostolopoulos, V., Mallet-Designe, V., Corper, A.L., Scott,
C.A., Wilson, I.A., Kang, A.S., and Teyton, L. (2000). J. Immunol. 165,
3214–3225.
Sutherland, A.P., Van Belle, T., Wurster, A.L., Suto, A., Michaud, M., Zhang, D.,
Grusby, M.J., and von Herrath, M. (2009). Diabetes 58, 1144–1155.
Tang, Q., Adams, J.Y., Tooley, A.J., Bi, M., Fife, B.T., Serra, P., Santamaria, P.,
Locksley, R.M., Krummel, M.F., and Bluestone, J.A. (2006). Nat. Immunol. 7,
83–92.
Tang, Q., Adams, J.Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E.,
Piccirillo, C.A., Salomon, B.L., and Bluestone, J.A. (2008). Immunity 28,
687–697.
The´bault-Baumont, K., Dubois-Laforgue, D., Krief, P., Briand, J.P., Halbout,
P., Vallon-Geoffroy, K., Morin, J., Laloux, V., Lehuen, A., Carel, J.C., et al.
(2003). J. Clin. Invest. 111, 851–857.
Thiessen, S., Serra, P., Amrani, A., Verdaguer, J., and Santamaria, P. (2002).
Diabetes 51, 325–338.
Tisch, R., and McDevitt, H. (1996). Cell 85, 291–297.
Todd, J.A. (2010). Immunity 32, this issue, 457–467.
Trudeau, J.D., Kelly-Smith, C., Verchere, C.B., Elliott, J.F., Finegood, D.T.,
Santamaria, P., and Tan, R. (2003). J. Clin. Invest. 111, 217–223.
Tsai, S., Shameli, A., and Santamaria, P. (2008). Adv. Immunol. 100, 79–124.
Tsai, S., Shameli, A., Yamanouchi, J., Clemente-Casares, X., Wang, J., Serra,
P., Yang, Y., Medarova, Z., Moore, A., and Santamaria, P. (2010). Immunity 32,
this issue, 568–580.Tsui, H., Chan, Y., Tang, L., Winer, S., Cheung, R.K., Paltser, G., Selvanan-
tham, T., Elford, A.R., Ellis, J.R., Becker, D.J., et al. (2008). Diabetes 57,
918–928.
Vafiadis, P., Bennett, S.T., Todd, J.A., Nadeau, J., Grabs, R., Goodyer, C.G.,
Wickramasinghe, S., Colle, E., and Polychronakos, C. (1997). Nat. Genet.
15, 289–292.
Vang, T., Congia, M., Macis, M.D., Musumeci, L., Orru´, V., Zavattari, P., Nika,
K., Tautz, L., Taske´n, K., Cucca, F., et al. (2005). Nat. Genet. 37, 1317–1319.
Vella, A., Cooper, J.D., Lowe, C.E., Walker, N., Nutland, S., Widmer, B., Jones,
R., Ring, S.M., McArdle, W., Pembrey, M.E., et al. (2005). Am. J. Hum. Genet.
76, 773–779.
Verdaguer, J., Yoon, J.W., Anderson, B., Averill, N., Utsugi, T., Park, B.J., and
Santamaria, P. (1996). J. Immunol. 157, 4726–4735.
Verdaguer, J., Schmidt, D., Amrani, A., Anderson, B., Averill, N., and
Santamaria, P. (1997). J. Exp. Med. 186, 1663–1676.
Vyse, T.J., and Todd, J.A. (1996). Cell 85, 311–318.
Wen, L., Ley, R.E., Volchkov, P.Y., Stranges, P.B., Avanesyan, L.,
Stonebraker, A.C., Hu, C., Wong, F.S., Szot, G.L., Bluestone, J.A., et al.
(2008). Nature 455, 1109–1113.
Wicker, L.S., Chamberlain, G., Hunter, K., Rainbow, D., Howlett, S., Tiffen, P.,
Clark, J., Gonzalez-Munoz, A., Cumiskey, A.M., Rosa, R.L., et al. (2004).
J. Immunol. 173, 164–173.
Wong, F.S., Karttunen, J., Dumont, C., Wen, L., Visintin, I., Pilip, I.M., Shastri,
N., Pamer, E.G., and Janeway, C.A., Jr. (1999). Nat. Med. 5, 1026–1031.
Wucherpfennig, K.W., Call, M.J., Deng, L., andMariuzza, R. (2009). Curr. Opin.
Immunol. 21, 590–595.
Yamanouchi, J., Verdaguer, J., Han, B., Amrani, A., Serra, P., and Santamaria,
P. (2003). J. Immunol. 171, 6900–6909.
Yamanouchi, J., Rainbow, D., Serra, P., Howlett, S., Hunter, K., Garner, V.E.,
Gonzalez-Munoz, A., Clark, J., Veijola, R., Cubbon, R., et al. (2007). Nat. Genet.
39, 329–337.
Yamanouchi, J., Puertas, M.C., Verdaguer, J., Lyons, P.A., Rainbow, D.B.,
Chamberlain, G., Hunter, K.M., Peterson, L.B., Wicker, L.S., and Santamaria,
P. (2010). Diabetes 59, 272–281.
You, S., Belghith, M., Cobbold, S., Alyanakian, M.A., Gouarin, C., Barriot, S.,
Garcia, C., Waldmann, H., Bach, J.F., and Chatenoud, L. (2005). Diabetes
54, 1415–1422.
Zhang, Y., O’Brien, B., Trudeau, J., Tan, R., Santamaria, P., and Dutz, J.P.
(2002). J. Immunol. 168, 1466–1472.
Ziegler, A.-G., and Nepom, G.T. (2010). Immunity 32, this issue, 468–478.Immunity 32, April 23, 2010 ª2010 Elsevier Inc. 445
